COMPARISON OF EFFICIENCY AND SAFETY Of CO-DIROTON, ENALAPRIL AND HYDROCHLOROTHIAZIDE IN PSORIATIC PATIENTS WITH ARTERIAL HYPERTENSION AND OVERWEIGHT


Cite item

Full Text

Abstract

Recent studies indicate a definite relationship of psoriasis and cardiovascular diseases. The article presents the results of study, which was aimed to evaluation of efficacy and safety of Co-Diroton, a fixed low-dose combination of lisinopril and hydrochlorothiazide (HCT) as compared with enalapril and hydrochlorothiazide in 83 psoriatic patients with arterial hypertension (AH) 1-2 degree and overweight . It was shown that administration of enalapril 10 mg/day, HCT 25 mg/day, or Co-Diroton 10/12.5 mg in this group of patients is safe, well tolerated and accompanied by a significant decrease in blood pressure (BP) without reducing the effectiveness of antipsoriatic therapy. Thus, Co-Diroton had significantly more antihypertensive effect than enalapril or hydrochlorothiazide as monotherapy: against the background of its use significantly more patients achieved target BP levels (83 vs 48 and 44 %).

References

  1. National Psoriasis Foundation. Psoriasis statistics. Доступно в сети Интернет по адресу: http://www.psoriasis.org Последнее обращение: 06.12.2010.
  2. Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis. Arch Dermatol 2007;143:1493-99.
  3. Nakagami T, Qiao Q, Tuomilehto J, et al. Screen-detected diabetes, hypertension and hypercholesterolemia as predictors of cardiovascular mortality in five populations of Asian origin: the DECODA study. Eur J Cardiovasc Prev Rehabil 2006;13(4):555-61.
  4. Pearce DJ, Morrison AE, Higgins KB, et al. The comorbid state of psoriasis patients in a university dermatology practice. J Dermatolog Treat 2005;16(5-6):319-23.
  5. Gelfand JM, Feldman SR, Stern RS, et al. Determinant of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol 2004;51:704-08.
  6. Qureshi АA, Choi HK, Setty AR, et al. Psoriasis and the Risk of Diabetes and Hypertension: A Prospective Study of US Female Nurses. Arch Dermatol 2009;145(4):379-82.
  7. Nakagami T, Qiao Q, Tuomilehto J, et al. Screen-detected diabetes, hypertension and hypercholesterolemia as predictors of cardiovascular mortality in five populations of Asian origin: the DECODA study. Eur J Cardiovasc Prev Rehabil 2006;13(4):555-61.
  8. Pearce DJ, Morrison AE, Higgins KB, et al. The comorbid state of psoriasis patients in a university dermatology practice. J Dermatol Treat 2005;16(5-6):319-23.
  9. Kim GK, Del Rosso JQ. Drug-Provoked Psoriasis: Is It Drug Induced or Drug Aggravated? Understanding Pathophysiology and Clinical Relevance. J Clin Aesthet Dermatol 2010;3(1):32-38.
  10. Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978;157:238-44.
  11. Адаскевич В.П. Диагностические индексы в дерматологии. Медицинская книга. М., 2004. С.107-108.
  12. Kimball AB, Gladman D, Gelfand JM, et al. National psoriasis foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008;58:1031-42.
  13. Dratelin CR, Martinez-Abundis E, Balcazar-Munoz BR, et al. Lipid profile, insulin secretion, and insulin sensitivity in psoriasis. J Am Acad Dermatol 2003;48:882-85.
  14. Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, et al. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 2001;303:33-39.
  15. Дворянкова Е.В., Шевченко А.О., Шевченко О.П., Новосельцев М.В., Орлова О.В., Гинзбург Л.М. Эффективность и безопасность симвастатина у больных распространенным псориазом // Дальневосточный вестник дерматовенерологии, косметологии и пластической хирургии. 2010. №1 (7). С. 22-26.
  16. Gelfand JM, Feldman SR, Stern RS, et al. Determinant of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol 2004;51:704-08.
  17. Ravipati G, Aronow WS, Ahn C, et al. Incidence of new stroke or new myocardial infarction or death at 39-month follow-up inpatients with diabetes mellitus, hypertension or both with and without microalbuminuria. Cardiology 2008;109(1):62-65.
  18. Gibson SH, Perry HO. Diabetes and psoriasis. AMA Arch Derm 1956;74(5):487-88.
  19. Cohen AD, Sherf M, Vidavsky L, et al. Association between psoriasis and the metabolic syndrome: a cross-sectional study. Dermatology 2008;216(2):152-55.
  20. Ravipati G, Aronow WS, Ahn C, et al. Incidence of new stroke or new myocardial infarction or death at 39-month follow-up in patients with diabetes mellitus, hypertension or both with and without microalbuminuria. Cardiology 2008;109(1):62-65.
  21. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55(5):829-35.
  22. Qureshi АA, Choi HK, Setty AR, et al. Psoriasis and the Risk of Diabetes and Hypertension: A Prospective Study of US Female Nurses. Arch Dermatol 2009;145(4):379-82.
  23. Al-Awadhi AM, Hasan EA, Sharma PN, et al. Angiotensin-converting enzyme gene polymorphism in patients with psoriatic arthritis. Rheumatol Int 2007;27(12):1119-23.
  24. Huskic J, Alendar F. Tissue angiotensin-converting enzyme in patients with various clinical forms of psoriasis. Bosn J Basic Med Sci 2007;7(2):103-06.
  25. Rodgers K, Xiong S, Felix J, et al. Development of angiotensin (1-7) as an agent to accelerate dermal repair. Wound Repair Regen 2001;9:238-47.
  26. Moscarelli L, Zanazzi M, Mancini G, et al. Keratinocyte cancer prevention with ACE inhibitors, angiotensin receptor blockers or their combination in renal transplant recipients. Clin Nephrol 2010;73(6):439-45.
  27. Шевченко А.О., Шевченко О.П. Фиксированная низкодозовая комбинация лизиноприла и гидрохлортиазида в профилактике сердечно-сосудистых событий у больных артериальной гипертонией // Рациональная фармакотерапия в кардиологии. 2010. № 6(5). C. 697-702.
  28. Epstein M, Bakris G. Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. Arch Intern Med 1996;156(17):1969-78.
  29. Patel BV, Remigio-Baker RA, Thiebaud P, et al. Improved persistence and adherence to diuretic fixed-dose combination therapy compared to diuretic monotherapy. BMC Fam Pract 2008;9:6.
  30. Motwani JG. Combining renin-angiotensin-aldosterone system blockade with diuretic therapy for treatment of hypertension. JRAAS 2002;3:72-8
  31. Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;326(7404):1427.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies